Symptomatic response to therapy with Rabeprazole Sodium does not preclude the presence of gastric or oesophageal malignancy, therefore the possibility of malignancy should be excluded prior to commencing treatment with RAZID 20. Although no evidence of significant drug related safety problems was seen in a study of patients with mild to moderate hepatic impairment versus normal age and sex matched controls, the prescriber is advised to exercise caution when treatment with RAZID 20 is first initiated in patients with severe hepatic dysfunction.